Tyler J Beardslee

A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease

R. Kudchadkar, K. Momary, J. Waltuck, 2022, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Precision, accuracy, and resolution—Dose selection of oral anticancer agents

R. Harvey, Tyler J Beardslee, Tyler J. Beardslee, 2016, Cancer.

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

W. Curran, G. Sica, F. Khuri, 2020, Journal for ImmunoTherapy of Cancer.

Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy

R. Kudchadkar, A. Draper, Tyler J Beardslee, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

R. Harvey, P. Medina, V. Adams, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation.

M. Bilen, S. Goyal, S. Caulfield, 2021, The oncologist.

Efficacy and safety of immune checkpoint blockade in self‐identified Black patients with advanced non–small cell lung cancer

T. Owonikoko, S. Ramalingam, Zhengjia Chen, 2020, Cancer.

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer

Tyler J Beardslee, J. Lawson, 2018, Journal of the advanced practitioner in oncology.

Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event

S. Ramalingam, E. Bryson, Tyler J Beardslee, 2020 .